ReviewMacromolecular rapid communications2026
Research Progress of Platinum-Based Anticancer Drugs in Combination with Macrocyclic Drug Delivery System.
Review in Macromolecular rapid communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Platinum-based anticancer drugs represent a cornerstone of clinical cancer chemotherapy, yet their clinical application is severely limited by inherent drug resistance and systemic toxic side effects. Macrocyclic compounds, such as cucurbiturils, cyclodextrins, crown ethers, calixarenes and pillararenes, possess unique cavity structures and excellent molecular recognition capabilities, offering promising strategies for optimizing the chemotherapeutic efficacy of platinum-based drugs. This review summarizes the latest research progress in supramolecular systems constructed from macrocyclic compounds and platinum-based drugs via host-guest interactions. It focuses on the roles of such supramolecular complexes in improving drug solubility, stability, tumor targeting, and controlled release performance, as well as their potential to overcome drug resistance and reduce toxicity. Furthermore, the applications of functionalized macrocyclic compounds in intelligent drug delivery and combination therapy are discussed, and future directions, including novel macrocyclic carriers, multifunctional nanoplatforms, and combination with immunotherapy and gene therapy, are prospected. This review aims to provide useful references for the development of precise and personalized applications of platinum-based drugs in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.